Ken Griffin Elevation Oncology, Inc. Call Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
Call Options
3 transactions
Others Institutions Holding ELEV
# of Institutions
70Shares Held
33.7MCall Options Held
65KPut Options Held
4K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$2.16 Million0.1% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.89MShares$2.12 Million1.64% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$1.71 Million0.08% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.02 Million0.26% of portfolio
-
Black Rock Inc. New York, NY2.49MShares$896,4890.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $8.39M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...